Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — MIMEDX GROUP, INC. (MDXG)
Filed: 2026-10-16 AccNo: 0001213900-26-110041 Size: 205 KB Item 8.01: Other Events
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MiMedx Group, Inc. announced it will report Q3 2026 financial results on October 28, 2026, followed by a webcast and conference call at 4:30 p.m. ET. The company also announced a favorable federal court ruling vacating FDA determinations regarding AXIOFILL's regulatory classification as a biological product.
MiMedx Group Announces U.S. Court Issues Favorable Ruling In Co.'s Litigation Against FDA's Regulatory Classification Of AXIOFILL
MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that the U.S. District Court for the Northern District of Georgia issued a favorable ruling in the Company’s litigation
8-K filing — Sanara MedTech Inc. (SMTI)
Filed: 2026-10-16 AccNo: 0001213900-26-110053 Size: 208 KB Item 8.01: Other Events
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX Group reported second quarter 2026 net sales of $64 million and reiterated its full year financial outlook. The company announced plans to acquire Sanara MedTech in a transformational combination aimed at creating a leading regenerative medicine company and expanding MIMEDX's surgical footprint across multiple surgical subspecialties.